<?xml version='1.0' encoding='utf-8'?>
<document id="22594566"><sentence text="Limitations of S-warfarin truncated area under the concentration-time curve to predict cytochrome P450 2c9 activity."><entity charOffset="15-25" id="DDI-PubMed.22594566.s1.e0" text="S-warfarin" /></sentence><sentence text="Phenotyping cytochrome P450 (CYP) 2C9 activity with S-warfarin requires extensive blood sampling to characterize area under the concentration-time curve (AUC)" /><sentence text=" This retrospective data analysis was conducted to determine if truncated S-warfarin AUCs can be used to measure CYP2C9 activity" /><sentence text="" /><sentence text="S-warfarin plasma concentrations were obtained from healthy adults (n = 84) genotyped as CYP2C9 extensive metabolizers (EMs) from 6 published studies"><entity charOffset="0-10" id="DDI-PubMed.22594566.s5.e0" text="S-warfarin" /></sentence><sentence text=" Subjects received a single 10 mg oral warfarin dose during baseline and treatment conditions" /><sentence text=" AUC zero to infinity (AUCINF) and truncated AUCs at 48 h (AUC(48)), at 72 h (AUC(72)) and at 96 h (AUC(96)) were determined by noncompartmental analysis" /><sentence text=" Equivalence was determined via least squares geometric mean ratios (LS-GMRs) with 90% confidence intervals (CI) within 0" /><sentence text="8-1" /><sentence text="25" /><sentence text="" /><sentence text="A lack of equivalence was observed for AUC(48) and AUC(72) compared to AUC(INF) during baseline conditions in all evaluated studies and during treatment conditions in 5 of 6 studies" /><sentence text=" Equivalence was observed for AUC(96) compared to AUC(INF) during all baseline and treatment conditions" /><sentence text=" Results were consistent across all evaluated AUCs between baseline and treatment without a CYP2C9-mediated drug-drug interaction and during induction with an oral contraceptive" /><sentence text=" During inhibition with fluvastatin, a lack of equivalence was observed with AUC(INF)(LS-GMR [90%CI] = 1"><entity charOffset="24-35" id="DDI-PubMed.22594566.s15.e0" text="fluvastatin" /></sentence><sentence text="25 [1" /><sentence text="16-1" /><sentence text="34]) and AUC(96) (1" /><sentence text="2 [1" /><sentence text="13=1" /><sentence text="27])" /><sentence text=" In contrast, equivalence was observed for AUC(48)(1" /><sentence text="15 [1" /><sentence text="08-1" /><sentence text="22]) and AUC(72) (1" /><sentence text="18 [1" /><sentence text="11-1" /><sentence text="24])" /><sentence text="" /><sentence text="S-warfarin truncated AUC(48) and AUC(72) poorly characterize AUC(INF) and are unable to detect weak CYP2C9 inhibition with fluvastatin"><entity charOffset="0-10" id="DDI-PubMed.22594566.s30.e0" text="S-warfarin" /><entity charOffset="123-134" id="DDI-PubMed.22594566.s30.e1" text="fluvastatin" /><pair ddi="false" e1="DDI-PubMed.22594566.s30.e0" e2="DDI-PubMed.22594566.s30.e0" /><pair ddi="false" e1="DDI-PubMed.22594566.s30.e0" e2="DDI-PubMed.22594566.s30.e1" /></sentence><sentence text=" S-warfarin phenotyping parameters need to ensure blood sampling of at least 96 h to characterize AUC and thus CYP2C9 activity" /><sentence text="" /></document>